Edition:
United States

Boule Diagnostics AB (BOUL.ST)

BOUL.ST on Stockholm Stock Exchange

259.50SEK
28 Apr 2017
Change (% chg)

15.00kr (+6.13%)
Prev Close
244.50kr
Open
244.50kr
Day's High
259.50kr
Day's Low
244.50kr
Volume
38,486
Avg. Vol
17,805
52-wk High
325.00kr
52-wk Low
63.00kr

BOUL.ST

Chart for BOUL.ST

About

Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that... (more)
No analyst recommendations are available for BOUL.ST.

Overall

Beta: 1.01
Market Cap(Mil.): kr1,221.50
Shares Outstanding(Mil.): 4.71
Dividend: 1.40
Yield (%): 0.54

Financials

  BOUL.ST Industry Sector
P/E (TTM): 34.46 51.37 30.08
EPS (TTM): 7.53 -- --
ROI: 15.48 6.70 13.25
ROE: 17.23 10.65 14.41

BRIEF-Boule Diagnostics wins strategic contract

* Installation of instruments will begin in Q2 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 17 2017

BRIEF-Boule Diagnostics Q4 operating profit grows to SEK 1.3 mln

* Q4 net sales 105.8 million Swedish crowns ($11.89 million) versus 88.4 million crowns year ago

Feb 16 2017

BRIEF-Boule Diagnostics Q4 operating profit up at SEK 1.3 mln

* Q4 net sales 105.8 million Swedish crowns ($12 million)versus 88.4 million crowns year ago

Feb 16 2017

BRIEF-Boule Diagnostics presents new targets, adjusts dividend policy

* Said on Wednesday had revised its financial targets and adjusted dividend policy

Feb 16 2017

BRIEF-Boule Diagnostics wins new contract in India

Jan 18 Boule Diagnostics AB : * Wins new procurement in India * Systems will be delivered during first quarter of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 18 2017

BRIEF-Tredje AP-fonden buys 7.6 pct stake in Boule Diagnostics

* Says Tredje AP-fonden buys 358,068 shares in Boule Diagnostics AB corresponding to 7.6 percent stake

Jan 17 2017

BRIEF-Boule Diagnostics names Fredrik Dalborg new CEO

* Dalborg to replace Ernst Westman, who will leave CEO post and company in Q1 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 10 2017

BRIEF-Boule Diagnostics Q3 operating profit up at SEK 24.8 mln

* Q3 net sales 108.5 million Swedish crowns ($12 million)versus 88.8 million crowns year ago

Nov 09 2016

More From Around the Web

Earnings vs. Estimates